Full-Time
Process Development Scientist
Piramal Pharma
1,001-5,000 employees
CDMO and hospital generics, consumer health
No salary listed
Riverview, MI, USA
In Person
Bachelor's, Master's, PhD
 Biology & Biotech (1) |
|---|
Get referred to Piramal Pharma
See people who can refer or advise you
- A PhD in Organic or Medicinal Chemistry and up to four years of experience in a relevant field, or an MS in Organic or Medicinal Chemistry and up to eight years of experience in a relevant field, or a BS in Organic or Medicinal Chemistry and up to twelve years of experience in a relevant field is required.
- Knowledge of organic chemistry and chemical safety is required.
- Familiarity with current good manufacturing practices, plant safety, and Environmental Protection Agency requirements is required.
- The candidate must have strong written, verbal, and interpersonal communication skills.
- The candidate must be able to direct projects covering a variety of chemical compounds, including highly potent active pharmaceutical ingredients.
- Develop, conduct, and/or manage the process development of current and new synthetic/process pathways, including routine analytical testing to monitor process progress using high-performance liquid chromatography, nuclear magnetic resonance, X-ray powder diffraction, gas chromatography headspace, Karl Fischer, and related methods.
- Scale up preparative high-performance liquid chromatography purification and lyophilization of intermediates and final products.
- Maintain communication with clients and ensure that their requirements are met.
- Manage or support the production of new highly potent active pharmaceutical ingredients and ensure that adequate supplies of process materials and operating equipment are available for assigned tasks.
- Ensure that product shipments meet customer and regulatory requirements, including requirements from the Food and Drug Administration, Environmental Protection Agency, and Occupational Safety and Health Administration.
- Write progress reports and provide technical support in meetings regarding current active pharmaceutical ingredient production and new active pharmaceutical ingredient process development.
- Ensure that approved processes are carried out according to current good manufacturing practice guidelines and are properly documented.
- Keep Quality Assurance and Quality Control departments updated regarding project or client requirements and schedules.
- Participate in the development, training, and transfer of new processes into the plant.
- Maintain accurate inventories of materials.
- Prepare reports as needed for management and clients.
- Maintain notebooks for research and development and non-current-good-manufacturing-practice activities.
- Complete and audit production and cleaning records, logbooks, dispensing records, batch production records, cleaning records, deviation reports, and related production and cleaning documentation according to regulatory requirements.
- Generate or evaluate standard operating procedures as required.
- Provide technical support for chemical operators, engineering, and quality control.
- Experience handling highly potent compounds and synthesizing and handling linker-payloads is highly desirable.
- The candidate should be self-motivated, creative, and independent.
- The candidate should have excellent organizational and planning skills.
Piramal Pharma operates through three divisions: Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and the Consumer Products Division (CPD). PPS acts as a contract development and manufacturing organization (CDMO), offering development and manufacturing services across the drug lifecycle for clients in North America, Europe, and Asia. PCC specializes in complex hospital generics, especially inhaled anesthetics, serving the USA, Europe, and more than 100 countries. CPD markets consumer health brands in India, including Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri Activ, and aims to provide reliable development, manufacturing, and distribution capabilities to meet customer needs.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
India
Founded
2020
Get referred to Piramal Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- April 28, 2026 FY26 revenue held at ₹8,869 crore; Kenalog adds $30-40 million annualized sales.
- Q4 FY26 cleared 30 inspections, including two US FDA visits without OAI findings.
- FY26 capex reached $94 million, while Lexington and Riverview expansions advanced toward FY27.
What critics are saying
- February 2026 Dahej closure over alleged hazardous dumping exposes Piramal to recurring plant shutdowns.
- Q4 FY26 growth suffered inventory destocking, slower early-stage orders, and weak ex-US anesthesia demand.
- Dahej shutdown plus repeat FDA findings can cripple PPS and PCC.
What makes Piramal Pharma unique
- Yapan Bio subsidiary deepens PPS biologics and ADC capabilities across vaccines, gene therapies, and ADCelerate.
- Piramal sells in 100-plus countries through 17 facilities and 6,000 hospitals.
- Kenalog and inhaled-anesthetic expertise combine complex manufacturing with entrenched hospital-channel distribution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Stock Options
Company News
Piramal Pharma Limited completes acquisition of controlling stake in Yapan Bio Private Limited. Aug 18, 2026, 15:36 ET * Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing. * This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services. MUMBAI, India, Aug. 18, 2026 /PRNewswire/ - Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL. Finalized on August 18, 2026, the acquisition marks a major step forward in PPL's long-range plan to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary's advanced large molecule capabilities into its integrated service offering, enabling the Company to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate(TM)- PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate(TM) and reinforces PPL's ability to deliver life-saving ADCs to market with speed and consistency. "This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action," said Peter DeYoung, CEO, Piramal Global Pharma. "By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need." About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. SOURCE Piramal Pharma Solutions
Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio for ₹76 crore, increasing its shareholding from 33.33% to 74%. The Mumbai-based pharmaceutical company purchased 146,400 equity shares, converting Yapan Bio from an associate company to a subsidiary. Yapan Bio, founded in 2019, is a Contract Development and Manufacturing Organisation specialising in vaccines and biologics. The company reported revenues of ₹26.91 crore, ₹54.40 crore, and ₹26.34 crore for fiscal years 2024, 2025, and 2026 respectively. The acquisition strengthens Piramal Pharma's biologics capabilities and expands its integrated service offerings. The company announced its intention to exercise this call option in August 2026, completing the transaction as disclosed in a regulatory filing to the National Stock Exchange.
Piramal Pharma Ltd invested INR 101.77 crore in Hyderabad-based Yapan Bio Pvt Ltd in December 2021, acquiring a 27.78% equity stake. The investment aimed to strengthen Piramal Pharma Solutions' CDMO capabilities in biologics and vaccines, particularly for large molecule development and manufacturing for human clinical trials. In April 2022, Piramal increased its stake by 5.55% for Rs 20.35 crore, bringing total ownership to 33.33% by March 2023. The company's FY2023 filings showed Yapan's share of loss at Rs 0.20 crore. In October 2022, Yapan expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, as part of a $1 million expansion plan. The facility supports end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. Yapan's services are marketed through Piramal Pharma Solutions.
Piramal Pharma expects to accelerate earnings growth over the next two to three years, driven by rising demand for complex drugs including targeted cancer therapies, chairperson Nandini Piramal said. The Indian drugmaker, which derives 55% of revenue from contract manufacturing, aims for early-to-mid-teens revenue growth after reporting a 3% drop in fiscal 2026. The company is prioritising higher-value segments, particularly antibody-drug conjugates for cancer treatment, as global biotech funding into Indian contract manufacturers rebounds. Biotech funding in the second half of 2024 was 80% higher year-on-year, translating into increased order inflows. Piramal is avoiding generic weight-loss drug ingredients due to intense competition and falling prices. The company's contract manufacturing revenue fell 10% last year, causing margins to shrink from 17% to 13%.
Piramal Pharma Limited announced results for Q4 and full-year FY26, reporting revenue growth impacted by inventory destocking, slower early-stage order inflows and softer inhalation anesthesia traction in ex-US markets. The company recognised an impairment loss of ₹176 crore on intangible assets under development. The pharmaceutical company invested $94 million in capex during FY26, with Lexington and Riverview expansions progressing. Net debt remained flat compared to FY25. Key developments included completing the Kenalog acquisition for $35 million upfront consideration plus up to $65 million contingent payment. The Consumer Healthcare division's Power Brands grew 24% year-on-year, whilst e-commerce sales surged 48%, contributing 27% to segment revenue. Chairperson Nandini Piramal stated all three business segments are positioned to deliver growth in FY27.